Predictive iPSC‑derived hepatocytes powering the next wave of translational toxicology
Wednesday, July 15 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Early‑stage drug discovery increasingly relies on liver models for physiologically relevant insight, yet many of these systems still lack the reliable and reproducible data needed for confident predictive toxicology. Primary human hepatocytes (PHHs) are the commonly used model for predictive screening of drug‑induced liver injury (DILI); however, their poor longevity in culture, batch variability, and limited availability make it challenging to identify liabilities early. The need for more scalable, consistent and high‑fidelity liver models has never been more critical.
To address these challenges, join Principal Scientist Dr. Gianmarco Mastrogiovanni in this SelectScience® webinar as he demonstrates how scalable, consistent ioHepatocytes can be applied for DILI prediction. Using opti‑ox™ deterministic cell programming, these iPSC‑derived hepatocytes achieve the reproducibility, scale and functional maturity needed to overcome PHH limitations, and Dr. Mastrogiovanni will show how their performance supports more reliable early ADME‑toxicology and safety assessment.
Register now to discover how reliable, high‑performance ioHepatocytes can accelerate smarter, safer drug development and reshape the future of early‑stage toxicology.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
Speakers
Who should attend?
- Professionals in biotechnology
- Pharmaceutical lab professionals
- Toxicologists
- CRO operation leads
- Pharmaceutical scientists
What will this webinar cover?
- The need for a scalable, highly consistent human cell model for predictive DILI screening and liver disease research
- The development, characterization and metabolic validation of hiPSC-derived ioHepatocytes powered by opti-ox™ deterministic cell programming
- How the incorporation of robust ioHepatocytes can act as a reliable tool for predictive toxicology and disease modelling
Join the webinar to get answers to these questions:
- How do next-generation iPSC-derived hepatocytes improve early-stage DILI prediction?
- In what ways do ioHepatocytes overcome the limitations of primary human hepatocytes?
- How does opti-ox™ deterministic programming enhance hepatocyte reproducibility and maturity?
- How can ioHepatocytes strengthen early ADME-toxicology and safety assessment workflows?
- How can scalable, high-fidelity liver models accelerate safer, more efficient drug development?
